Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: physical function

Glucosamine Supplements Don’t Help Knee or Hip Arthritis Pain

Carolyn Crist  |  August 10, 2017

(Reuters Health)—Oral glucosamine has no more effect than placebo on joint pain, according to a new meta-analysis. The analysis of randomized controlled trials from which data have been made public found that at both three-month and 24-month follow-up points, the supplement had no effect on either hip or knee pain from arthritis. Even sub-groups, such…

Filed under:Drug Updates Tagged with:glucosamine supplementsjoint pain cureoral glucosamineOsteoarthritis Research Society InternationalU.S. National Institute for Health and Care Excellence

Mind-Body Techniques for Pain Management

Lara C. Pullen, PhD  |  July 14, 2017

CHICAGO—Delia Chiaramonte, MD, associate director of education at the Center for Integrative Medicine at the University of Maryland School of Medicine in Baltimore, presented the newest thinking on pain to a gathering of rheumatologists at the ACR’s State-of-the-Art Clinical Symposium in April. She began by explaining that pain is more than nociception. Nociception stimulates nerves to…

Filed under:ConditionsMeeting ReportsPain SyndromesResearch Rheum Tagged with:2017 State of the Art Clinical SymposiumAC&RAmerican College of Rheumatology (ACR)braincentral nervous systemFibromyalgiameditationmindPain ManagementResearchrheumatologyyoga

News Updates for Diclofenac Sodium, Denosumab & Sarilumab

Michele B. Kaufman, PharmD, BCGP  |  June 20, 2017

In drug news, a generic 2% diclofenac sodium solution is now available, denosumab is promising to treat osteoporosis, and the FDA has approved sarilumab to treat adults with RA…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabdiclofenac sodiumFDAFood and Drug Administrationgeneric drugsKnee Osteoarthritis (OA)OsteoporosisRheumatoid Arthritis (RA)sarilumab

FDA Responds to New Drug Application for Baricitinib

Michele B. Kaufman, PharmD, BCGP  |  June 15, 2017

Oxycodone Tablets Submitted to FDA Filings for oxycodone tablets (Oxaydo) in both 10 and 15 mg doses have been accepted by the U.S. Food and Drug Administration (FDA).1 The submission is based on a pharmacokinetic study demonstrating bioequivalence to the reference drug, oxycodone hydrochloride (Roxicodone) tablets at a 15 mg dose. The product is an…

Filed under:AnalgesicsConditionsDrug Updates Tagged with:analgesicApprovalsbaricitinibDisease-modifying antirheumatic drugs (DMARDs)drugFDAopioidOxycodonePsoriatic ArthritisQualityRARheumatoid arthritisSafetysecukinumabupdate

Centrexion’s Chili-Based Painkiller Offers Relief for 6 Months—Study

Natalie Grover  |  June 14, 2017

(Reuters)—A synthetic version of a medicine traditionally extracted from chili plant relieved knee pain among osteoarthritis patients for up to six months, data showed, bringing Centrexion Therapeutics a step closer to developing a safe and effective analgesic. The drug, designed to be injected at the site of pain, is being developed by the privately-held company…

Filed under:Drug UpdatesOsteoarthritis and Bone Disorders Tagged with:CentrexionChili-Based PainkillerCNTX-4975knee pain

Rocketclips, Inc./shutterstock.com

Tips for Managing Young Adult Rheumatology Patients

Gregory Taylor, MSW, RCSW  |  May 18, 2017

Often, young adults (18–23 years old) with rheumatic illness demonstrate poor adherence to treatment regimens, lack advocacy skills and have inadequate knowledge about diagnosis and treatment.1 Patients presenting at a transition clinic are typically comfortable with having their parents continue to be centrally involved with their care, but this is a time in life when…

Filed under:ConditionsPediatric ConditionsPractice Support Tagged with:Association of Rheumatology Professionals (ARP)communicationhealthManagementpatient carePediatricphysician patient relationshippsychosocialRheumatic DiseaserheumatologistrheumatologytransitionTreatment

Rheumatology Drug Updates: Sirukumab Promising for RA, Plus Efficacy Duration of Ustekinumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  May 16, 2017

Sirukumab Promising for RA Sirukumab, an investigational human monoclonal antibody that selectively binds to the interleukin (IL) 6 cytokine, has completed a randomized, double-blind, placebo-controlled, parallel-group, Phase 3 clinical trial (SIRROUND-T) in patients with rheumatoid arthritis (RA).1 During the trial, which took place between July 25, 2012, and Jan. 12, 2016, researchers randomized adult patients…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis

Rheumatologists Respond to Prescription Opioid Analgesic Crisis

Larry Beresford  |  May 16, 2017

The alarming statistics on prescription opioid overdoses are well known to medical professionals, thanks to the Centers for Disease Control and Prevention (CDC)’s widely cited finding that deaths from opioid analgesics have increased fourfold since 1999.1 Half of all fatal drug overdoses now involve opioids prescribed by a doctor. Meanwhile, a lack of rigorous research…

Filed under:AnalgesicsConditionsDrug UpdatesPain SyndromesPractice Support Tagged with:AddictionanalgesicChronic painepidemicManagementopioidOverdosepatient careprescriptionRheumatic DiseaserheumatologistrheumatologyriskSafetyTreatment

FDA to Review Immediate-Release Oxycodone; Plus NICE Recommends Secukinumab

Michele B. Kaufman, PharmD, BCGP  |  May 1, 2017

A new formulation of oxycodone in 10 and 15 mg doses is being reviewed by the FDA for treating pain…

Filed under:AnalgesicsBiologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:FDAFood and Drug AdministrationOpioidsPsoriatic Arthritissecukinumab

Mindfulness-Based Stress Reduction Only Slightly Improves Low Back Pain

Will Boggs, MD  |  April 26, 2017

(Reuters Health)—Mindfulness-based stress reduction programs (MSBR) appear to improve low back pain only slightly, and only temporarily, a review of previous research suggests. These programs combine meditation while sitting and walking, yoga, focusing attention on different parts of the body and incorporation of mindfulness/awareness into everyday life. Earlier studies found MBSR to be helpful for…

Filed under:ConditionsPain SyndromesSoft Tissue Pain Tagged with:Back painChronic painlow back painmindfulness

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 80
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences